|
GEP20084317B
(en)
|
2000-04-25 |
2008-02-25 |
Icos Corp |
Inhibitors of human phosphatidyl-inositol 3-kinase delta
|
|
US6667300B2
(en)
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
|
GB0119863D0
(en)
|
2001-08-14 |
2001-10-10 |
Cancer Res Campaign Tech |
DNA-PK inhibitors
|
|
GB2405870B
(en)
*
|
2001-08-14 |
2005-07-06 |
Cancer Rec Tech Ltd |
DNA-PK inhibitors
|
|
GB0119865D0
(en)
*
|
2001-08-14 |
2001-10-10 |
Cancer Res Campaign Tech |
DNA-PK inhibitors
|
|
US20040235866A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Takahisa Hanada |
Lymphocytic activation inhibitor and remedial agent for autoimmune disease
|
|
US7049313B2
(en)
|
2002-02-25 |
2006-05-23 |
Kudos Pharmaceuticals Ltd. |
ATM inhibitors
|
|
AR038703A1
(es)
|
2002-02-28 |
2005-01-26 |
Novartis Ag |
Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
|
|
EP2311818B1
(en)
*
|
2002-02-28 |
2013-01-16 |
Novartis AG |
Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
|
|
US7598377B2
(en)
*
|
2002-08-16 |
2009-10-06 |
Astrazeneca Ab |
Inhibition of phosphoinositide 3-kinase β
|
|
CN100430389C
(zh)
*
|
2002-08-16 |
2008-11-05 |
阿斯利康(瑞典)有限公司 |
抑制磷酸肌醇3-激酶β
|
|
EP1572113B1
(en)
|
2002-08-26 |
2017-05-17 |
Takeda Pharmaceutical Company Limited |
Calcium receptor modulating compound and use thereof
|
|
WO2004052373A1
(en)
*
|
2002-12-06 |
2004-06-24 |
Warner-Lambert Company Llc |
Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
|
|
GB0305152D0
(en)
|
2003-03-06 |
2003-04-09 |
Novartis Ag |
Organic compounds
|
|
AU2004230841A1
(en)
|
2003-04-03 |
2004-10-28 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
|
AU2004228668B2
(en)
*
|
2003-04-03 |
2011-10-27 |
Park Funding, Llc |
PI-3 kinase inhibitor prodrugs
|
|
US20040259926A1
(en)
*
|
2003-06-05 |
2004-12-23 |
Bruendl Michelle M. |
3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
|
|
CA2527934A1
(en)
*
|
2003-06-05 |
2004-12-16 |
Warner-Lambert Company Llc |
Tetrazol benzofurancarboxamides with p13k activity as therapeutic agents
|
|
BRPI0410940A
(pt)
*
|
2003-06-05 |
2006-08-29 |
Warner Lambert Co |
benzo[b]tiofenos substituìdos com cicloalquilsulfanila como agentes terapêuticos
|
|
AU2004265149A1
(en)
|
2003-08-13 |
2005-02-24 |
Kudos Pharmaceuticals Limited |
Aminopyrones and their use as ATM inhibitors
|
|
JP2007504209A
(ja)
*
|
2003-09-04 |
2007-03-01 |
ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー |
ＰＩ３Ｋ阻害活性を有する治療薬としてのハロゲン置換ベンゾ（ｂ）チオフェン類
|
|
DE602004007284T2
(de)
*
|
2003-10-31 |
2008-02-28 |
Warner-Lambert Company Llc |
PYRIMIDINE ALS INHIBITOREN VON PHOSPHOINOSITID-3-KINASEN (PI3Ks)
|
|
AU2005228845A1
(en)
*
|
2004-01-26 |
2005-10-13 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
|
WO2005113556A1
(en)
|
2004-05-13 |
2005-12-01 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
|
CN1300163C
(zh)
*
|
2004-06-23 |
2007-02-14 |
南京大学 |
3－羟基色原酮糖苷及其制法和用途
|
|
BRPI0515498A
(pt)
|
2004-09-20 |
2008-07-29 |
Kudos Pharm Ltd |
inibidores de dna-pk
|
|
EP1848712A1
(en)
|
2005-02-09 |
2007-10-31 |
Kudos Pharmaceuticals Ltd |
Atm inhibitors
|
|
AR053358A1
(es)
|
2005-04-15 |
2007-05-02 |
Cancer Rec Tech Ltd |
Inhibidores de adn - pk
|
|
US7691858B2
(en)
|
2006-04-25 |
2010-04-06 |
Targegen, Inc. |
Kinase inhibitors and methods of use thereof
|
|
US8163760B2
(en)
*
|
2006-06-22 |
2012-04-24 |
Prana Biotechnology Limited |
Use of pyridopyrimidine compounds in the treatment of gliomas
|
|
US8106071B2
(en)
*
|
2007-02-21 |
2012-01-31 |
Biobud Co., Ltd. |
Compositions for treating hyperproliferative vascular disorders and cancers
|
|
EP2157092A4
(en)
|
2007-04-11 |
2011-04-13 |
Ajinomoto Kk |
Remedy for diabetes
|
|
WO2008150827A1
(en)
*
|
2007-05-29 |
2008-12-11 |
Smithkline Beecham Corporation |
Naphthyridine, derivatives as p13 kinase inhibitors
|
|
US20100130597A1
(en)
*
|
2007-07-06 |
2010-05-27 |
The United State Of America, As Represented By The Secretary Of The Dept Of Health And Human Service |
Dna-pkcs modulates energy regulation and brain function
|
|
RU2010133715A
(ru)
*
|
2008-01-25 |
2012-02-27 |
Астразенека Аб (Se) |
ЭНАНТИОМЕРНО ЧИСТАЯ (-)2-[1-(7-МЕТИЛ-2-(МОРФОЛИН-4-ИЛ)-4-ОКСО-4Н-ПИРИДО[1,2-a]ПИРИМИДИН-9-ИЛ)БЕНЗОЙНАЯ КИСЛОТА, ЕЕ ПРИМЕНЕНИЕ В ФАРМАКОТЕРАПИИ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЕЕ
|
|
EP2262366A4
(en)
*
|
2008-04-18 |
2012-02-22 |
Shenogen Pharma Group Ltd |
COMPOUNDS AND METHODS FOR TREATING STROGEN RECEPTOR-RELATED DISEASES
|
|
MX2011003373A
(es)
|
2008-09-29 |
2011-06-09 |
Sirtris Pharmaceuticals Inc |
Quinazolinona, quinolona y analogos relacionados como moduladores de sirtuina.
|
|
US8110578B2
(en)
*
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
|
KR20160091440A
(ko)
|
2008-11-13 |
2016-08-02 |
길리아드 칼리스토가 엘엘씨 |
혈액 종양에 대한 요법
|
|
SG10201402867TA
(en)
|
2009-07-02 |
2014-08-28 |
Sanofi Sa |
Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
|
|
WO2011001115A1
(fr)
|
2009-07-02 |
2011-01-06 |
Sanofi-Aventis |
Nouveaux derives de 6-morpholin-4-yl-pyrimidin-4- ( 3h ) -one, leur preparation pharmaceutique comme inhibiteurs de phos phorylat i on d ' akt ( pkb )
|
|
HUE034503T2
(en)
|
2009-07-02 |
2018-02-28 |
Sanofi Sa |
2,3-Dihydro-1-imidazo [1,2-a] pyrimidin-5-one derivatives, their preparation process and their use in medicine
|
|
CN102482286B
(zh)
|
2009-07-02 |
2015-07-15 |
赛诺菲 |
新型1,2,3,4-四氢嘧啶并{1,2-a}嘧啶-6-酮衍生物、其制备以及其医药用途
|
|
CA2768843A1
(en)
|
2009-07-21 |
2011-01-27 |
Gilead Calistoga Llc |
Treatment of liver disorders with pi3k inhibitors
|
|
US8399460B2
(en)
|
2009-10-27 |
2013-03-19 |
Astrazeneca Ab |
Chromenone derivatives
|
|
IT1403156B1
(it)
*
|
2010-12-01 |
2013-10-04 |
Università Degli Studi Di Torino |
Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi.
|
|
FR2969613B1
(fr)
*
|
2010-12-23 |
2013-02-08 |
Sanofi Aventis |
Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique
|
|
FR2969612B1
(fr)
*
|
2010-12-23 |
2013-02-08 |
Sanofi Aventis |
Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique
|
|
DK2655375T3
(en)
|
2010-12-23 |
2015-03-09 |
Sanofi Sa |
PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF
|
|
US9133168B2
(en)
|
2010-12-28 |
2015-09-15 |
Sanofi |
Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
|
|
WO2013111850A1
(ja)
*
|
2012-01-26 |
2013-08-01 |
第一三共株式会社 |
骨形成促進作用を有するクロモン誘導体
|
|
DK2812004T3
(en)
*
|
2012-02-10 |
2018-10-15 |
Ptc Therapeutics Inc |
COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY
|
|
CN104302181B
(zh)
|
2012-03-01 |
2017-09-15 |
Ptc医疗公司 |
用于治疗脊髓性肌萎缩的化合物
|
|
NZ629684A
(en)
|
2012-03-05 |
2016-10-28 |
Gilead Calistoga Llc |
Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
|
|
KR102109992B1
(ko)
|
2012-03-23 |
2020-05-13 |
피티씨 테라퓨틱스, 인크. |
척수성 근위축증을 치료하기 위한 화합물
|
|
ITMI20120514A1
(it)
*
|
2012-03-29 |
2013-09-30 |
Cnr Consiglio Naz Delle Ric Erche |
Agente terapeutico per il trattamento dei vasi sanguigni
|
|
FR2992314B1
(fr)
|
2012-06-22 |
2015-10-16 |
Sanofi Sa |
Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
|
|
EP3082820B1
(en)
|
2013-12-19 |
2022-07-20 |
PTC Therapeutics, Inc. |
Methods for modulating the amount of rna transcripts
|
|
NZ736970A
(en)
|
2013-12-20 |
2018-11-30 |
Gilead Calistoga Llc |
Process methods for phosphatidylinositol 3-kinase inhibitors
|
|
WO2015095605A1
(en)
|
2013-12-20 |
2015-06-25 |
Gilead Calistoga Llc |
Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
|
|
MA40059A
(fr)
|
2014-06-13 |
2015-12-17 |
Gilead Sciences Inc |
Inhibiteurs de la phosphatidylinositol 3-kinase
|
|
EP3298017B1
(en)
*
|
2015-05-20 |
2019-08-14 |
H. Hoffnabb-La Roche Ag |
Compounds for treating spinal muscular atrophy
|
|
EP4249472A3
(en)
|
2015-05-30 |
2023-12-13 |
PTC Therapeutics, Inc. |
Methods for modulating rna splicing
|
|
IL294124B2
(en)
|
2015-12-10 |
2024-02-01 |
Ptc Therapeutics Inc |
Methods for treating huntington's disease
|
|
EP3390378B1
(en)
|
2015-12-17 |
2022-03-30 |
AlonBio Ltd. |
Small molecules against cancer
|
|
AU2016371466B2
(en)
|
2015-12-17 |
2020-04-09 |
Alonbio Ltd |
Small Molecules for Inhibiting Chemokine Activity and/or Cancer Cells Growth
|
|
CA3033667A1
(en)
*
|
2016-08-12 |
2018-02-15 |
Nanjing Gator Meditech Company, Ltd. |
Protein kinase regulators
|
|
EA201991309A1
(ru)
|
2016-11-28 |
2019-11-29 |
|
Способы модуляции сплайсинга рнк
|
|
EP3573619A4
(en)
|
2017-01-27 |
2020-10-28 |
SignalRX Pharmaceuticals, Inc. |
THIENOPYRANONES AND FURANOPYRANONES AS KINASE, BROMODOMAIN AND CHECKPOINT INHIBITORS
|
|
US11407753B2
(en)
|
2017-06-05 |
2022-08-09 |
Ptc Therapeutics, Inc. |
Compounds for treating Huntington's disease
|
|
KR20200017476A
(ko)
|
2017-06-14 |
2020-02-18 |
피티씨 테라퓨틱스, 인크. |
Rna 스플라이싱의 변경 방법
|
|
US11382918B2
(en)
|
2017-06-28 |
2022-07-12 |
Ptc Therapeutics, Inc. |
Methods for treating Huntington's Disease
|
|
WO2019005993A1
(en)
|
2017-06-28 |
2019-01-03 |
Ptc Therapeutics, Inc. |
METHODS OF TREATING HUNTINGTON'S DISEASE
|
|
MX2020009957A
(es)
|
2018-03-27 |
2021-01-15 |
Ptc Therapeutics Inc |
Compuestos para el tratamiento de enfermedad de hungtinton.
|
|
PL3814357T3
(pl)
|
2018-06-27 |
2024-09-16 |
Ptc Therapeutics, Inc. |
Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
|
|
EP3814345B8
(en)
|
2018-06-27 |
2024-10-30 |
PTC Therapeutics, Inc. |
Heteroaryl compounds for treating huntington's disease
|
|
EP3814360B8
(en)
|
2018-06-27 |
2024-11-06 |
PTC Therapeutics, Inc. |
Heteroaryl compounds for treating huntington's disease
|
|
CN109748914B
(zh)
*
|
2018-12-29 |
2021-05-25 |
上海珂臻医药科技有限公司 |
吡啶并嘧啶类化合物及其应用
|
|
WO2020231977A1
(en)
|
2019-05-13 |
2020-11-19 |
Ptc Therapeutics, Inc. |
Compounds for treating huntington's disease
|
|
ES3014809T3
(en)
|
2019-05-15 |
2025-04-25 |
Alonbio Ltd |
Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death
|
|
AR121719A1
(es)
|
2020-04-03 |
2022-06-29 |
Petra Pharma Corp |
Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
|
|
CN111533721B
(zh)
*
|
2020-05-15 |
2022-04-26 |
浙江大学 |
苯并吡喃酮或喹啉酮类化合物及其应用
|
|
WO2021247859A1
(en)
*
|
2020-06-03 |
2021-12-09 |
Yumanity Therapeutics, Inc. |
Pyridopyrimidines and methods of their use
|
|
WO2022164812A1
(en)
*
|
2021-02-01 |
2022-08-04 |
Geode Therapeutics Inc. |
Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof
|
|
KR20240004865A
(ko)
|
2021-05-03 |
2024-01-11 |
페트라 파마 코포레이션 |
질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제
|
|
EP4347040A1
(en)
|
2021-05-27 |
2024-04-10 |
Petra Pharma Corporation |
Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of cancer
|
|
TW202329930A
(zh)
|
2021-09-30 |
2023-08-01 |
美商佩特拉製藥公司 |
用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
|
|
EP4412606A4
(en)
*
|
2021-10-07 |
2025-09-24 |
Relay Therapeutics Inc |
PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
|
|
WO2025136936A1
(en)
*
|
2023-12-19 |
2025-06-26 |
Merck Sharp & Dohme Llc |
Agonists of trem2 activity
|